Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304145 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Christian Bjerregård Øland und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Pharmacoepidemiology, LEO Pharma A/S, Ballerup, Denmark. Hauptthemen laut MEDLINE: Tacrolimus, Lymphoma, T-Cell, Cutaneous, Bias. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LEO Pharma.
Abstract (Originalsprache)
Background
Reverse causation is a challenge in many drug-cancer associations, where the cancer symptoms are potentially mistaken for drug indication symptoms. However, tools to assess the magnitude of this type of bias are currently lacking. We used a simulation-based approach to investigate the impact of reverse causation on the association between the use of topical tacrolimus and cutaneous T-cell lymphoma (CTCL) in a multinational, population-based study using topical corticosteroids (TCS) as comparator.
Methods
We used a multistate model to simulate patients’ use over time of a first- (TCS) and second-line treatment (topical tacrolimus), onset of atopic dermatitis (indication for drugs) and CTCL (the studied outcome). We simulated different scenarios to mimic real-life use of the two treatments. In all scenarios, it was assumed that there was no causal effect of the first- or second-line treatment on the occurrence of CTCL. Simulated data were analysed using Cox proportional hazards models.
Results
The simulated hazard ratios (HRs) of CTCL for patients treated with tacrolimus vs. TCS were consistently above 1 in all 9 settings in the main scenario. In our main analysis, we observed a median HR of 3.09 with 95% of the observed values between 2.11 and 4.69.
Conclusions
We found substantial reverse causation bias in the simulated CTCL risk estimates for patients treated with tacrolimus vs. TCS. Reverse causation bias may result in a false positive association between the second-line treatment and the studied outcome, and this simulation-based framework can be adapted to quantify the potential reverse causation bias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biostatistics and Pharmacoepidemiology, LEO Pharma A/S, Ballerup, Denmark.
ORCID-Profile: Christian Bjerregård Øland, Tea Skaaby, Christian Bressen Pipper
Förderung
- LEO Pharma
Zitieren
APA
Øland, C. B., Ranch, L. S., Skaaby, T., Delvin, T., Jakobsen, H. B., & Pipper, C. B. (2024). Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome. PLOS ONE. https://doi.org/10.1371/journal.pone.0304145
Vancouver
Øland CB, Ranch LS, Skaaby T, Delvin T, Jakobsen HB, Pipper CB. Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome. PLOS ONE. 2024. doi:10.1371/journal.pone.0304145
BibTeX
@article{land2024,
author = {Øland, Christian Bjerregård and Ranch, Lise Skov and Skaaby, Tea and Delvin, Thomas and Jakobsen, Henny Bang and Pipper, Christian Bressen},
title = {Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304145}
}
EUVIMED